ReviewInternational journal of molecular sciences2016
Transition Metal Intercalators as Anticancer Agents-Recent Advances.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 85 citations in OpenAlex.
- Heterometallic Multinuclear Ruthenium Complexes as Cytotoxic Agents.Biomedicines · 2026Review
- Electrochemical Investigation, Photoactive DNA Cleavage, Computational, Antioxidant, and Anticancer Activities on Bi-Imidazole-Based Ru (II) Complexes.Journal of fluorescence · 2026Article
- Cycloruthenated Imines: A Step into the Nanomolar Region.Molecules (Basel, Switzerland) · 2026Article
- Anticancer Activity of Schiff Base Metal Complexes Against MCF-7 Breast Cancer Cell Line.International journal of molecular sciences · 2026Review
- Optimization of Antiproliferative Properties of Triimine Copper(II) Complexes.Journal of medicinal chemistry · 2024Article
- Recently Reported Biological Activities and Action Targets of Pt(II)- and Cu(II)-Based Complexes.Molecules (Basel, Switzerland) · 2024Review
- The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs.International journal of molecular sciences · 2023Review
- Dichloro Ru(II)-ACS pharmacology & translational science · 2023Review
- Current Developments ofBiomedicines · 2022Review
- Synthesis, characterization, antimicrobial and cytotoxic activity and DNA-binding properties of d-metal complexes with hydrazones of Girard's T and P reagents.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2021Article
- Arene Ruthenium(II) Complexes Bearing the κ-Molecules (Basel, Switzerland) · 2021Article
- Practical and Computational Studies of Bivalence Metal Complexes of Sulfaclozine and Biological Studies.Frontiers in chemistry · 2021Article
- Design, synthesis and biomedical evaluation of mostotrin, a new water soluble tryptanthrin derivative.International journal of molecular medicine · 2020Article
- Evaluation of the Anticancer Activities of Novel Transition Metal Complexes with Berenil and Nitroimidazole.Molecules (Basel, Switzerland) · 2020Article
- Recent development of nucleic acid nanosensors to detect sequence-specific binding interactions: From metal ions, small molecules to proteins and pathogens.Sensors international · 2020Article
- Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.Radiology and oncology · 2019Review
- Stabilization of Long-Looped i-Motif DNA by Polypyridyl Ruthenium Complexes.Frontiers in chemistry · 2019Article
- Recent Advances in Copper Intercalators as Anticancer Agents.Journal of fluorescence · 2018Review
- Rhodium metalloinsertor binding generates a lesion with selective cytotoxicity for mismatch repair-deficient cells.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Photochemically active DNA-intercalating ruthenium and related complexes - insights by combining crystallography and transient spectroscopy.Chemical science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diverse anticancer utility of cisplatin has stimulated significant interest in the development of additional platinum-based therapies, resulting in several analogues receiving clinical approval worldwide. However, due to structural and mechanistic similarities, the effectiveness of platinum-based therapies is countered by severe side-effects, narrow spectrum of activity and the development of resistance. Nonetheless, metal complexes offer unique characteristics and exceptional versatility, with the ability to alter their pharmacology through facile modifications of geometry and coordination number. This has prompted the search for metal-based complexes with distinctly different structural motifs and non-covalent modes of binding with a primary aim of circumventing current clinical limitations. This review discusses recent advances in platinum and other transition metal-based complexes with mechanisms of action involving intercalation. This mode of DNA binding is distinct from cisplatin and its derivatives. The metals focused on in this review include Pt, Ru and Cu along with examples of Au, Ni, Zn and Fe complexes; these complexes are capable of DNA intercalation and are highly biologically active.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.